Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma

Zargari, Nooshin; Mokhtari, Maral

doi:10.1159/000494430

Cited by 22 publications

(30 citation statements)

References 13 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TROP2 possesses sites for tyrosine/serine phosphorylation that regulate signal transduction or its expression and activity, thereby rendering cancer cells resistant to apoptosis [32]. Upregulated TROP2 correlates with the poor prognosis of thyroid papillary carcinoma [33], colon cancer [34], liver cancer [35], and other malignancies.…”

Section: Discussionmentioning

confidence: 99%

Tissue mechanics and expression of TROP2 in oral squamous cell carcinoma with varying differentiation

Zhang

Gao

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: Trophoblast cell surface antigen 2 (TROP2) is overexpressed in many squamous cell carcinomas and promotes tumor development and invasion. The association between TROP2 expression and occurrence and development of oral squamous cell carcinoma (OSCC) remains to be understood. Methods: We investigated the role of TROP2 in OSCC patients using a combination of biophysical approaches. A total of 108 OSCC patient specimens with varying degrees of differentiation were subjected to hematoxylin and eosin staining, immunohistochemistry, Kaplan-Meier survival curve analysis, and atomic force microscopy to analyze TROP2 expression, morphology, and mechanical properties of OSCC tissues. Results: TROP2 was overexpressed in 34% of poorly differentiated OSCC samples. High levels of TROP2 were associated with 10.2% survival rate lower than 45.4% and patient age (odds ratio [OR] = 0.437, P = 0.039, 95% confidence interval [CI, 0.198-0.966]), tumor size (OR = 13.148, P = 0.000, 95% CI [5.060-34.168]), and TNM stage (OR = 0.141, P = 0.000, 95% CI [0.082-0.244]). Average surface roughness of low, medium, and highly differentiated OSCC tissues were 448.9 ± 54.8, 792.7 ± 83.6, and 993.0 ± 104.3 nm, respectively. The Pearson coefficient revealed a negative association between tumor stiffness and TROP2 expression (r = − 0.84, P < 0.01). Conclusion: Overexpression of TROP2 negatively associated with patient survival, degree of tumor differentiation, and tissue mechanics. Taken together, our findings demonstrated that TROP2 may be an indicator of OSCC differentiation leading to the altered mechanical properties of OSCC tissues.

show abstract

Section: Discussionmentioning

confidence: 99%

Tissue mechanics and expression of TROP2 in oral squamous cell carcinoma with varying differentiation

Zhang

Gao

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…As for the thyroid tumors, the previous studies have shown the potential utility of TROP-2 as a useful diagnostic tool for PTC in surgical and cytology specimens and the differential expression of TROP-2 in benign and malignant thyroid lesions. 6-10,22-25 Among them, Bychkov et al evaluated TROP-2 expression in a variety of thyroid cancers including PTC, FTC, insular or poorly differentiated carcinoma, and ATC. 6 Their study demonstrated most of the PTCs (94/114, 82.5%) and none of the 35 FTC cases to be immunopositive for TROP-2.…”

Section: Discussionmentioning

confidence: 99%

TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma

et al. 2020

View full text Add to dashboard Cite

Background Anaplastic thyroid carcinoma (ATC), a highly aggressive malignancy, has no effective treatment to date. Trophoblast cell-surface antigen 2 (TROP-2), a transmembrane glycoprotein, has been suggested to be a promising novel target for sacituzumab govitecan, an antibody-drug conjugate. 5-Hydroxymethylcytosine (5hmC) has a role in tumor suppression and promoting modification. Additionally, isocitrate dehydrogenase 1 (IDH1) mutations are strongly associated with increased overall survival in gliomas and worse prognosis in leukemias. This study attempts to evaluate the immunoexpression of TROP-2, 5hmC, and IDH1 in ATCs and to determine their potential impact in targeted therapy. Methods Twenty-four ATCs were retrieved, with 9 cases that occurred de novo and 15 cases derived from either papillary thyroid carcinoma (PTC) or follicular thyroid carcinoma (FTC). Sections were immunostained with TROP-2, 5hmC, and IDH1 antibodies, and evaluated using the QuPath program. The t tests were performed using SPSS software. Results TROP-2 was detected in 12 ATCs with 9 cases demonstrating a high expression and in all PTC components, and absent in all FTC components of secondary ATCs. 5hmC expression was moderately reduced in PTC and FTC components and markedly reduced in ATC. The entire cohort showed a total absence of IDH1. Conclusions Increased TROP-2 immunoexpression in some ATCs supports that these patients may potentially benefit from an antibody-drug conjugate therapy targeting TROP-2. Markedly reduced 5hmC expression suggests that 5hmC may be used as potential therapeutic targets for ATC. The total lack of IDH1 R132H mutation by immunostain indicates that it has no prognostic and therapeutic value in ATC.

show abstract

“…TROP2 possesses sites for tyrosine/serine phosphorylation that regulate signal transduction or regulatory factor, thereby imparting resistance to apoptosis in cancer cells [32]. Upregulated TROP2 correlates with the poor prognosis of thyroid papillary carcinoma [33], colon cancer [34], liver cancer [35], and other malignant tumors.…”

Section: Discussionmentioning

confidence: 99%

Tissue Mechanics and Expression of TROP2 in Oral Squamous Cell Carcinoma with Varying Differentiation

Zhang

Gao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Trophoblast cell surface antigen 2 (TROP2) is overexpressed in many squamous cell carcinomas and contributes to tumor development and invasion. The correlation between the expression of TROP2 and occurrence and development of oral squamous cell carcinoma (OSCC) remains to be understood. MethodsWe have investigated the role of the specific marker TROP2 in OSCC patients using a combination of biophysics approaches. Analyzed 108 OSCC patient specimens with varying degrees of differentiation using hematoxylin and eosin staining and immunohistochemistry for TROP2 expression, along with Kaplan-Meier survival curve analysis and atomic force microscopy, to understand the morphology and mechanical properties of OSCC tissues. ResultsIn total, 34% poor differentiation underwent high TROP expression. TROP2 as risk factor about patient age (OR = 0.437, P = 0.039), tumor size (OR = 13.148, P = 0.000), TNM stage (OR = 0.141, P = 0.000) during low survival rate. Average surface roughness of low, medium, and highly differentiated OSCC tissues were 448.9 ± 54.8, 792.7 ± 83.6, and 993.0 ± 104.3 nm, respectively. The Pearson coefficient revealed a negative correlation between stiffness and TROP2 expression (r=-0.84, P < 0.01).Conclusion TROP2 expression increased with the decrease in survival rate and negatively correlated with the various degrees of differentiation and tissue mechanics. Taken together, our findings demonstrate that TROP2 may be an indicator of OSCC differentiation that leads to the altered mechanical properties (e.g., stiffness) of OSCC tissues.

show abstract

Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma

Cited by 22 publications

References 13 publications

Tissue mechanics and expression of TROP2 in oral squamous cell carcinoma with varying differentiation

Tissue mechanics and expression of TROP2 in oral squamous cell carcinoma with varying differentiation

TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma

Tissue Mechanics and Expression of TROP2 in Oral Squamous Cell Carcinoma with Varying Differentiation

Contact Info

Product

Resources

About